Chromosomal Instability clinical trials at UCLA
1 research study open to eligible people
Showing trials for
Sovilnesib in Subjects with Ovarian Cancer
open to eligible females ages 18 years and up
This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).
Los Angeles, California and other locations
Last updated: